This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Patients with atrialfibrillation, particularly older patients, are frequently at a high risk of bleeding. In patients with atrialfibrillation, abelacimab reduced rates of bleeding relative to rivaroxaban regardless of bleeding risk, with greater absolute safety benefit in those at higher bleeding risk.
in which a monoclonal antibody targeting factors XI and XIa was evaluated for its effects on bleeding events in patients with atrialfibrillation. This editorial describes the science behind a clinical trial reported by Ruff et al.
Interruption of the inferior vena cava (IVC) is a rare vascular anomaly resulting from aberrant development during embryogenesis, deep venous thrombosis or extrinsic tumor compression.1 2-4 We aimed to describe the procedural steps, safety and efficacy of AF ablation using transhepatic access.
The left atrial appendage dangles off the left atrial chamber in the heart and has long been suspected of being a nidus for clot that can break off and cause a stroke. The treatment of patients with atrialfibrillation has always involved powerful blood thinners to prevent formation of clot.
BackgroundPercutaneous left atrial appendage closure (LAAC) serves as an alternative prophylactic strategy for patients with non-valvular atrialfibrillation (AF) who cannot undergo anti-coagulation therapy. The pericardial effusion or tamponade likely resulted from damage to the atrial appendage during LAAC device insertion.
Bleeds were adjudicated using International Society on Thrombosis and Haemostasis criteria. Epistaxis events were less severe than nonepistaxis bleeds (International Society on Thrombosis and Haemostasis major: 3.2% Among 5247 patients with a bleeding event, 1008 (19.2%) had epistaxis and 4239 (80.8%) had nonepistaxis bleeding.
Abstract: This study seeks to identify the anticoagulant efficacy of rivaroxaban treatment on thrombi detected using echocardiography of the left atrial appendage in 275 patients with persistent atrialfibrillation (AF). 35.68, P=0.028) as factors related to left atrial appendage thrombus. P=0.008), 3D-EF (OR 6.4,
The primary efficacy and safety end points were stroke or systemic embolism and major bleeding (International Society on Thrombosis and Hemostasis definition), respectively. Journal of the American Heart Association, Ahead of Print. 0.80]; >45 kg: HR, 0.31 [95% CI, 0.13–0.73]; 0.73]; interactionP=0.82).
Left atrial appendage (LAA) thrombus is the primary cause of stroke and systemic embolism in atrialfibrillation (AF). Novel oral anticoagulants (NOACs) effectively reduce the prevalence of LAA thrombosis and stroke risk.
AI-ECG prediction models developed at our institution can evaluate the probability of atrialfibrillation (AF) and estimate a patients age based on a normal sinus rhythm (NSR) ECG. Migraine with aura(MwA) is associated with an increased risk of stroke and adverse vascular outcomes compared to those with migraine without aura (MwoA).
Publication date: Available online 7 March 2024 Source: The American Journal of Cardiology Author(s): Federica Troisi, Pietro Guida, Nicola Vitulano, Federico Quadrini, Antonio Di Monaco, Giuseppe Patti, Massimo Grimaldi
Introduction Interventional closure of the left atrial appendage (LAAC) has been established as an alternative treatment for patients with atrialfibrillation (AF) and an elevated risk of stroke.
However, the presence of residual trabeculation did not contribute to PDL or device-related thrombosis at follow-up or affect the clinical outcomes. ABSTRACT Background Research on the impact of angiographically detected residual trabeculation after left atrial appendage closure (LAAC) is limited. vs. 1.4%, p =0.50; 6.9%
We recruited three groups of patients: ICAS-LVOS, LVOS caused by atrialfibrillation (AF) and symptomatic ICAS (sICAS) without LVOS. Clinical information and lab results were collected and analyzed.Results:A total of 279 patients were included, comprising 70 ICAS-LVOS patients, 78 AF-LVOS patients, and 131 sICAS patients.
Historically, the research literature overwhelmingly emphasized the future hemorrhagic risk associated with CMBs, potentially leading to unnecessary withholding of treatments proven effective at preventing thrombosis, such as anticoagulants in patients with atrialfibrillation who happened to have some microbleeds.
Harvard University Heart Letter) A clinical polygenic risk score test for diseases ranging from atrialfibrillation (AFib) to breast cancer was piloted by scientists. Avocado consumption of at least two servings per week is linked to a lower risk of cardiovascular disease.
Patients were drawn from neurology, cardiology, and other services. Descriptive statistics were used to compare trends across these groups.Results:Of the 3,966 patients, AF was the most common diagnosis (47.16% self-pay, 67.14% insured), followed by DVT and PE.
The prospect of uncoupling the management of thrombosis from the bleeding risk inadvertently associated with current therapy inspired the development of agents directed towards this step in the coagulation process.
Case submitted and written by Mazen El-Baba MD, with edits from Jesse McLaren and edits/comments by Smith and Grauer A 90-year old with a past medical history of atrialfibrillation, type-2 diabetes, hypertension, dyslipidemia, presented with acute onset chest/epigastric pain, nausea, and vomiting.
The rhythm is atrialfibrillation. As in all ischemia interpretations with OMI findings, the findings can be due to type 1 AMI (example: acute coronary plaque rupture and thrombosis) or type 2 AMI (with or without fixed CAD, with severe regional supply/demand mismatch essentially equaling zero blood flow).
underlying atrialfibrillation or atrial inactivity). For this analysis, ACO was defined as angiographic evidence of coronary thrombosis with peak cardiac troponin-I (cTn-I) at least 10 ng/mL or cTn-T ≥ 1 ng/ mL. Since you cannot see the pacing spikes, how would you know it is paced without the computer read?
Objective Antithrombotic therapy is essential for patients with atrialfibrillation (AF) and stable coronary artery disease (CAD) because of the high risk of thrombosis, whereas a combination of antiplatelets and anticoagulants is associated with a high risk of bleeding.
A point-scoring system was generated by the β-coefficients of the variables independently associated with the long-term risk of arterial thrombosis, and the predictive MUCH score was calculated as the sum of the weighted scores.RESULTS:Overall, 1729 patients (median follow-up time, 43 months [25th to 75th percentile, 69.0]) qualified for inclusion.
A third of patients (32.3%) had a history of atrialfibrillation, and 11.8% In a recent article published in JACC: Cardiovascular Interventions, investigators presented comprehensive examination of both short- and long-term stroke risks post-TAVR, offering insights into evolving trends and predictors. at 5 years.
IntroductionCerebral venous thrombosis (CVT) is an uncommon form of stroke with relatively low mortality but higher incidence in younger adults.1–3 IntroductionCerebral venous thrombosis (CVT) is an uncommon form of stroke with relatively low mortality but higher incidence in younger adults.1–3 annually for White patients, 16.1%
BackgroundLeft atrial appendage occlusion (LAAO) serves as an alternative to oral anticoagulation (OAC) for atrialfibrillation (AF) patients at high risk of bleeding.
BackgroundLeft atrial appendage closure (LAAC) is an alternative to oral anticoagulation for stroke prevention in non-valvular atrialfibrillation (AF). Selecting the appropriate size of Watchman device is very important intra-procedure. 2 patients (1.2%) occurred pericardial tamponade after procedure.
However, after the procedure, moderate pericardial effusion developed in one patient (0.7%) and an acute pulmonary embolism related to femoral vein thrombosis was observed in one patient (0.7%) during the first month. All of the patients had a >10 mm long-tunnel PFO.ResultsThe procedural success rate was 100%.
2:34 PM, following right heart catheterization She then went into atrialfibrillation with complete heart block and junctional escape rhythm prompting placement of transvenous pacemaker. The catheter was out of the body and the arteriotomy had been closed, so there is no pressure waveform.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content